Roberts A P, Eastwood J B, Gower P E, Fenton C M, Curtis J R
Eur J Clin Pharmacol. 1978 Dec 18;14(6):435-9. doi: 10.1007/BF00716386.
Serum levels of clindamycin bioactivity and total clindamycin were studied after single intramuscular injections of 300 mg of clindamycin phosphate in a group of 6 normal subjects and a group of 6 maintenance haemodialysis patients. The patients were studied during a non-dialysis period and then again during haemodialysis. Peak levels tended to be higher and elimination half-lives shorter in the patients than in the normal subjects. Possible reasons for these differences are discussed. There was no evidence that haemodialysis per se influenced the pharmacokinetics of clindamycin phosphate. The proportion of unhydrolysed clindamycin phosphate tended to be higher in the renal failure patients and the reason for this is not apparent. Little, if any, dosage modification is necessary in severe renal fialure although there is probably little point in exceeding a dose of 300 mg intramuscularly every 5 h even in severe infections in patients with severe renal failure. The higher peak levels in patients with advanced renal failure indicate the need for further studies with repeated doses.
在一组6名正常受试者和一组6名维持性血液透析患者中，单次肌内注射300mg克林霉素磷酸酯后，研究了血清中克林霉素生物活性水平和总克林霉素水平。在非透析期和血液透析期间对患者进行了研究。与正常受试者相比，患者的峰值水平往往更高，消除半衰期更短。讨论了这些差异的可能原因。没有证据表明血液透析本身会影响克林霉素磷酸酯的药代动力学。肾衰竭患者中未水解的克林霉素磷酸酯比例往往更高，其原因尚不清楚。在严重肾衰竭时，几乎不需要调整剂量，尽管即使在严重肾衰竭患者的严重感染中，每5小时肌内注射超过300mg的剂量可能也没有什么意义。晚期肾衰竭患者较高的峰值水平表明需要对重复给药进行进一步研究。
